Shire Adderall XR
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Once-daily formulation of the company's attention deficit hyperactivity disorder therapy Adderall (mixed salts of a single entity amphetamine product) is "approvable" Aug. 3. The company expects to receive approval by the end of the year